RLY-5836
- Generic Name
- RLY-5836
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Phase 1
Completed
- Conditions
- HER2-negative Breast CancerBreast CancerUnresectable Solid TumorPIK3CA MutationSolid Tumor, AdultHormone Receptor Positive TumorMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath